Psybio Therapeutics Corp Stock Analysis
| PSYBF Stock | USD 0.0001 0.00 0.00% |
PsyBio Therapeutics Corp is undervalued with Real Value of 0.002712 and Hype Value of 9.3E-5. The main objective of PsyBio Therapeutics pink sheet analysis is to determine its intrinsic value, which is an estimate of what PsyBio Therapeutics Corp is worth, separate from its market price. There are two main types of PsyBio Therapeutics' stock analysis: fundamental analysis and technical analysis.
The PsyBio Therapeutics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and PsyBio Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
PsyBio |
PsyBio Pink Sheet Analysis Notes
About 26.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.09. PsyBio Therapeutics Corp last dividend was issued on the 18th of October 2016. PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. Psybio Therapeautics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.The quote for PsyBio Therapeutics Corp is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about PsyBio Therapeutics Corp contact Evan Levine at 513 449 9585 or learn more at https://www.psybiolife.com.PsyBio Therapeutics Corp Investment Alerts
| PsyBio Therapeutics is way too risky over 90 days horizon | |
| PsyBio Therapeutics has some characteristics of a very speculative penny stock | |
| PsyBio Therapeutics appears to be risky and price may revert if volatility continues | |
| PsyBio Therapeutics Corp has accumulated 207.81 K in total debt with debt to equity ratio (D/E) of 7.03, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PsyBio Therapeutics Corp has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PsyBio Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, PsyBio Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PsyBio Therapeutics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PsyBio to invest in growth at high rates of return. When we think about PsyBio Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (11.02 M) with loss before overhead, payroll, taxes, and interest of (1.56 M). | |
| PsyBio Therapeutics Corp has accumulated about 911.83 K in cash with (6.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 26.0% of PsyBio Therapeutics outstanding shares are owned by corporate insiders |
PsyBio Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate PsyBio Therapeutics's market, we take the total number of its shares issued and multiply it by PsyBio Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 16th of December 2024, PsyBio Therapeutics holds the Variance of 6620260.56, coefficient of variation of 819.35, and Risk Adjusted Performance of 0.0985. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of PsyBio Therapeutics, as well as the relationship between them. Please check PsyBio Therapeutics Corp risk adjusted performance, standard deviation, as well as the relationship between the Standard Deviation and maximum drawdown to decide if PsyBio Therapeutics Corp is priced some-what accurately, providing market reflects its current price of 1.0E-4 per share. As PsyBio Therapeutics Corp appears to be a penny stock we also advise to check out its information ratio numbers.PsyBio Therapeutics Corp Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. PsyBio Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for PsyBio Therapeutics Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
PsyBio Therapeutics Predictive Daily Indicators
PsyBio Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of PsyBio Therapeutics pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
PsyBio Therapeutics Forecast Models
PsyBio Therapeutics' time-series forecasting models are one of many PsyBio Therapeutics' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary PsyBio Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About PsyBio Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how PsyBio Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling PsyBio shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as PsyBio Therapeutics. By using and applying PsyBio Pink Sheet analysis, traders can create a robust methodology for identifying PsyBio entry and exit points for their positions.
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. Psybio Therapeautics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding PsyBio Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Complementary Tools for PsyBio Pink Sheet analysis
When running PsyBio Therapeutics' price analysis, check to measure PsyBio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PsyBio Therapeutics is operating at the current time. Most of PsyBio Therapeutics' value examination focuses on studying past and present price action to predict the probability of PsyBio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PsyBio Therapeutics' price. Additionally, you may evaluate how the addition of PsyBio Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |